智飞生物(300122) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 reached ¥8,841,150,250.19, representing a 125.16% increase compared to ¥3,926,600,928.88 in the same period last year[1] - Net profit attributable to shareholders was ¥1,922,756,886.80, up 104.95% from ¥938,179,113.58 year-on-year[1] - Operating costs for Q1 2022 were ¥6,503,327,142.16, up from ¥2,756,078,603.71 in the same period last year, indicating an increase of about 136.5%[16] - Net profit for Q1 2022 was ¥1,922,756,886.80, compared to ¥938,179,113.58 in Q1 2021, reflecting a growth of approximately 104.3%[18] - The net profit margin for Q1 2022 was approximately 21.7%, compared to 23.9% in Q1 2021, indicating a slight decline in profitability[19] - Basic and diluted earnings per share for Q1 2022 were both ¥1.2017, up from ¥0.5864 in Q1 2021, reflecting an increase of approximately 104.3%[19] Cash Flow - The net cash flow from operating activities was -¥3,316,743,954.40, a significant decline of 2,814.44% compared to -¥113,803,717.67 in the previous year[1] - Total cash inflow from operating activities is 5,120,358,696.65 CNY, up from 2,651,288,724.02 CNY in the previous period[21] - Cash outflow from operating activities totals 8,437,102,651.05 CNY, compared to 2,765,092,441.69 CNY in the previous period, reflecting increased operational costs[21] - The net cash flow from financing activities increased by 169.74% to ¥1,412,329,711.67, attributed to a reduction in repayments of short-term loans[8] - Cash flow from financing activities shows a net inflow of 1,412,329,711.67 CNY, a substantial increase from 523,588,052.11 CNY in the previous period[21] - The company paid 1,199,335,368.80 CNY in taxes during the current period, significantly higher than 440,557,817.58 CNY in the previous period[21] - Cash and cash equivalents at the end of the period amount to 1,961,452,199.09 CNY, compared to 1,304,768,272.67 CNY at the end of the previous period[21] Assets and Liabilities - Total assets increased by 3.94% to ¥31,232,017,191.18 from ¥30,047,323,465.36 at the end of the previous year[2] - The company's total liabilities decreased to ¥11,652,047,392.55 at the end of Q1 2022 from ¥12,390,110,553.53 at the beginning of the year, a reduction of approximately 5.9%[16] - The company's equity attributable to shareholders rose by 10.89% to ¥19,579,969,798.63 from ¥17,657,212,911.83[2] - The total current assets increased to 25,573,666,529.61 from 24,753,780,404.17, indicating a growth in liquidity[14] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 30.41% to ¥16,781,140,653.65, driven by sustained sales growth[5] - The accounts receivable rose to 16,781,140,653.65 from 12,867,543,957.77, reflecting an increase in sales or credit extended to customers[14] - The inventory decreased to 6,624,995,699.96 from 7,385,396,274.99, suggesting improved inventory management or reduced production[14] Research and Development - Research and development expenses surged by 161.12% to ¥160,890,893.91, reflecting increased investment in R&D projects[7] - Research and development expenses for Q1 2022 amounted to ¥160,890,893.91, significantly higher than ¥61,614,846.81 in Q1 2021, representing an increase of about 160.5%[18] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 89,963, with the top ten shareholders holding significant stakes, including Jiang Rensheng at 48.32%[9] - The total number of shares held by the top ten unrestricted shareholders includes Jiang Rensheng with 171,677,250 shares, indicating strong insider ownership[10] Product Issuance and Collaborations - The company reported a significant increase in the issuance of its products in Q1 2022, with the four-valent HPV vaccine issuance up by nearly 70% to 2.11 million doses, and the nine-valent HPV vaccine issuance up by 280% to 4.83 million doses[12] - The company continues its collaboration with Merck, focusing on increasing product supply to cover more eligible populations[12] Financial Management - The company is actively managing its financial assets, with a notable amount of 239,000,000 in other equity investments[14] - The company invested 409,610,155.15 CNY in fixed assets and intangible assets, down from 488,586,891.27 CNY in the previous period[21] - The company received 1,691,545,450.00 CNY in borrowings, slightly up from 1,593,398,716.00 CNY in the previous period[21] Exchange Rate Impact - The impact of exchange rate changes on cash and cash equivalents was -4,224,148.33 CNY, compared to a positive impact of 182,292.02 CNY in the previous period[21] Employee Engagement - The company has implemented an employee stock ownership plan, which was approved in early 2022, to enhance employee engagement and retention[11]